



BioQentix AI Private Limited

# BioQentix AI Pitch Deck

Transforming Multi-AI Engine Driven  
Pharma/Biotech Virtual Novel Drug Discovery &  
Development



🔍 <https://BioQentix.info> ✕



**BioQentix AI Private Limited**

# About The Company –

## ➤ Who we are:

- ✓ BioQentix AI is a next generation Multi-AI engine driven Pharma/Biotech R&D platform

## ➤ Focus on:

- ✓ Multi-AI driven Biologics/Biosimilars/small molecules drug discovery
- ✓ Multi-AI driven Pre-Clinical, Clinical, Drug Repurpose, Reformulation

## ➤ Platform integrates:

- ✓ Multi-AI, Quantum AI, Big Database, Deep-Tech, Data Learning & Machine learning

## ➤ Mission:

- ✓ Reduce Pharma/Biotech drug discovery & development time and cost
- ✓ Enable personalized medicine at scale

02





**BioQentix AI Private Limited**



**03**

# Problem Statement

- Traditional Drug Discovery is slow, costly and with compliance issues
- 10–15 years to develop a drug
- USD 5–7 million before clinical trials for small drug molecules and USD 1-5 Billions for Biologics.
- 90% failure rate
- Limited Patient access across globe
- Heavy chemical/biological waste
- High animal use and ethical concerns



# Problem Solution

- **Multi-AI Driven Drug Discovery Engine:** Quantum-AI + Generative-AI platform producing virtual, patent-ready drug molecules at ultra-low cost with more than 90% Accuracy
- **High-Speed R&D Cycle:** Reduce 4-7 years in drug discovery and development with automated AI pipelines, multiple drug development at a time
- **Scalable and Regulatory Compliant:** Near-zero marginal cost for each additional molecule → infinite scalability and fully REGULATORY COMPLIANT and easy patient reach globally
- **Minimal Animal and Chemical waste:** Minimal animal use with no ethical concern; minimal biological and chemical waste.



**BioQentix AI Private Limited**

# Technology Platform

## Overview of Technology Platform

05

**A**

**Target (Disease) Identification**

**B**

**Multi-AI Driven Model Designing**

**C**

**Quantum AI Simulation**

**D**

**Multi-AI driven parameters Optimization and validation**

**E**

**Patent & Lab Ready Molecule**




BioQentix AI Private Limited

# Product Tech

## Software working flow diagram

06





**BioQentix AI Private Limited**

07

# Market Opportunity

## Target Market

- Pharmaceutical and Biotech companies seeking advanced AI-driven drug discovery and development solutions.
- Our platform serves R&D teams focused on accelerating clinical trials and optimizing formulations.
- CROs involved in drug discovery under strict regulatory requirements
- Pharmaceutical and Biotech companies looking to revive the failed drugs

## Market Size

- The Biologics and Biosimilars growing at CAGR ~10% to reach USD 800+ Billions by 2030
- Small Drug Discovery market is growing at CAGR ~ 8% to reach USD 140+ Billions by 2030
- Drug repurpose market size : TAM USD 40+ Billions with CAGR ~4-4.5%
- Reformulation market size ~USD 100 Billions by 2030 with CAGR ~ 4%

## Growth Potential



- Adoption of AI technologies in pharma R&D is increasing rapidly.
- Strategic partnerships and continuous platform innovation support scalable and long-term growth.
- 0-2 years services and partnerships-~\$10M
- 3-5 years AI platform licensing – USD \$20-100M
- 5-10 years own strong pipelines – USD500M+
- Patent Expires by 2030



**BioQentix AI Private Limited**

# Market Opportunity

**TAM • SAM • SOM** for BioQentix



## TAM

Total market for your product.

## SAM

Percentage of SAM you can realistically capture.

## SOM

Portion of the market you can acquire based on your business model (your targets).



**BioQentix AI Private Limited**

# Product and Services

## ➤ Multi-AI engine driven Platform:


- ✓ Novel Drug Discovery
- ✓ Biologics & Large molecules Drug R&D
- ✓ Biosimilar R&D
- ✓ Drug Repurpose R&D
- ✓ Pre-clinical Research
- ✓ Clinical R&D optimization
- ✓ Failed clinical trial regeneration
- ✓ Reformulation R&D
- ✓ Cell and Gene advanced therapeutics
- ✓ Multi-Omics Intelligence



Multi-AI Engine Driven  
Biologics & Large Molecule Drug  
R&D Platform



Multi-AI Engine Driven  
Novel Drug Discovery Platform





# Business Model

## ➤ Revenue Model

- ✓ SaaS-based subscription plans
- ✓ Customized enterprise solutions
- ✓ Consulting services clinical trial optimization and, drug repurpose and reformulation

## ➤ Key Partnerships

- ✓ Pharma and Biotech Company partnership
- ✓ CROs and medical research institutes
- ✓ Strategic collaborations for platform enhancement

## ➤ Growth Strategy

- ✓ Targeted marketing and industry events
- ✓ Continuous platform innovation for scalable growth

## ➤ IPO in next 2-3 years



**BioQentix AI Private Limited**

11

# Key Metrics



- **Time Compression: Saves 4-7 years in drug discovery with more accuracy and high speed**
- **Pipeline Productivity: Lead identification and optimization speed  
More percentage of predicted drugs advance to lab validations**

- **High scalability with compatibility with regulatory compliances**
- **Commercial and ROI: Huge cost saving  
Percentage of pilot success leads to pivotal success, early market, more revenue**



BioQentix AI Private Limited

# Competitive Analysis

12

Feature	BioQentix AI	Recursion	Schrödinger	Exscientia	Insilico Medicine
~ 1 Billion Indian Patient database (for Clinical studies)	√	X	X	X	X
Digital Twin Model	√	X	X	X	X
End-to-End solution	√	X	X	X	X
Easy Scalable	√	√	X	X	√
Low cost	√	X	X	X	X






**BioQentix AI Private Limited**

# Tractions So Far...

- ✓ DPIIT registered
- ✓ MSME registered
- ✓ Patent filed for BioQentix AI Novel Drug Discovery platform
- ✓ Copyright filed for CRISPR-QUANT-GPT
- ✓ Collaboration with BioHUB Labs, USA
- ✓ Drug Discovery, BioSimilar, Biologics, Pre-Clinical and Clinical platform are validated and Live









# Go-to-Market Strategy —

- Global Pharma companies
- Global Biotech companies
- CRDMOs
- CROs
- Consulting
- Research Institutes & Global universities



# Financial Projections

- Adoption of AI technologies in pharma R&D is increasing rapidly. Strategic partnerships and continuous platform innovation support scalable and long-term growth.
  - ✓ 0-2 years: Services and partnerships - ~\$10M
  - ✓ 3-5 years: AI platform licensing – USD \$20-100M
  - ✓ 5-10 years: Own strong pipelines – USD 500M+
- Patent expires by 2030.
  - ✓ **Most of patents are expiring by 2030, market will open to all, resulting sharp fall in prices**
  - ✓ Its right time to create a robust pipeline of novel drugs for sustainable growth over coming years.





**BioQentix AI Private Limited**

16

# Our Team




**Dr Dharam Prakash Srivastava**

- More than 25 years of rich industrial experience in Drug Discovery
- Expert: Quantum AI, Generative AI and multiple proprietary AI models powered virtual software developer
- Expert: TMCP, Clinical Bioanalysis, Biomarker, Clinical Pharmacology
- Single dose pharmacokinetics, studies, metabolite profiling across various species.



**Sarvesh Goel**

- More than 26 years of rich industrial experience in Formulation and analytical development
- Pharmaceutical development and quality analysis
- Expert in multi-AI driven formulation-integrated analytical development
- Experienced in managing high-end analytical labs & driving end-to-end product lifecycle
- Strong track record in regulatory compliance eg USFDA, MHRA, TGA, EMA, WHO



# The Ask: USD 5 Millions




Field	USD
AI/ML & Quantum computing Development	1.5 M
Big data Infrastructure	1.5 M
Global patent and regulatory Intelligence	0.6 M
Commercialization and Collaborations	0.6 M
Operations, Security and Talen Acquisition	0.6 M
Clinical validation and strategic reserve	0.2 M



# Exit Strategy —

- Global Pharma/Biotech Acquisition
- Partnership buyout option
- IPO listing in next 2-3 years
- Secondary sales and VC buyout





**BioQentix AI Private Limited**

# Thank You.

*Join us in building the one of world's first fully  
end-to-end virtual drug discovery powerhouse*



**+91-99711 20306**  
**+91-99304 96871**



**[AI@BioQentix.info](mailto:AI@BioQentix.info)**



**<https://BioQentix.info>**